Income Taxes Period for which Research Tax Credit Extended for Qualified Research Expenditures Incurred Through End of Specified Period
Period for which research tax credit extended for qualified research expenditures incurred through the end of 2013
Represents the period for which research tax credit is extended in respect of qualified research expenditures incurred through the end of specified period.
Exercise Price Dollars 2.68 [Member]
$2.68
Represents the exercise price of 2.68 dollars per share.
Exercise Price Dollars 4.00 [Member]
$4.00
Represents the exercise price of 4.00 dollars per share.
Exercise Price Dollars 6.04 [Member]
$6.04
Represents the exercise price of 6.04 dollars per share.
Class of Warrant or Right Number of Securities for which Warrants will Become Exercisable in Event of Conversion of Preferred Stock into Common Stock
Number of shares for which warrant will become exercisable in the event of conversion of outstanding Series C convertible preferred stock into common stock
Represents the number of securities for which warrants will become exercisable in the event of conversion of outstanding convertible preferred stock into common stock.
Class of Warrant or Right Number of Securities in Aggregate for which Warrants will Become Exercisable in Event of Conversion of Preferred Stock into Common Stock
Number of aggregate shares for which warrant will become exercisable in the event of conversion of outstanding Series C convertible preferred stock into common stock if Company draws down the second term loan
Represents the aggregate number of securities for which warrant will become exercisable in the event of conversion of outstanding convertible preferred stock into common stock if entity draws down the second term loan.
Class of Warrant or Right Exercise Price of Warrants or Rights in Event of Conversion of Preferred Stock into Common Stock
Exercise price of warrants in the event of conversion of outstanding Series C convertible preferred stock into common stock (in dollars per share)
Represents the exercise price per share or per unit of warrants or rights outstanding in the event of conversion of outstanding convertible preferred stock into common stock.
Number of countries outside United States in which marketing authorization is obtained
Represents the number of countries outside United States in which marketing authorization is obtained under the agreement.
Collaborative Arrangement Number of Countries Outside United States in which Marketing Authorization is Obtained
Additional payments that may be received
Represents the additional payments that may be received under the agreement.
Collaborative Arrangement Addition Payments that May be Received
Collaborative Arrangement Addition Payments that May be Received for Each Country Outside United States in which Entity Obtains Marketing Authorization and Achieves Specified Level of Reimbursement
Additional payments that may be received for each country outside of the United States in which the company obtains marketing authorization and achieves a specified level of reimbursement
Represents the additional payments that may be received for each country outside of the United States in which the entity obtains marketing authorization and achieves a specified level of reimbursement under the agreement.
Amendment Description
Collaborative Arrangement Number of Countries Outside United States for which Additional Payments May be Received
Number of countries outside United States for which additional payments may be received
Represents the number of countries outside United States for which additional payments may be received under the agreement.
Amendment Flag
Collaborative Arrangement Percentage of Cash Receipts of Co-Promotion Fees for Remaining Periods
Percentage of cash receipts of co-promotion fees received by co-promoter for remaining periods
Represents the percentage of cash receipts of co-promotion fees received and to be received by the co-promoter under the agreement for the remaining periods.
Collaborative Arrangement Maximum Amount to be Spent by CoPromoter for Qualifying Clinical Development Activities in Countries that Require Additional Testing for Approval
Maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing
Represents the maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing for approval under the agreement.
Collaborative Arrangement Co Promotion Fee Amortization Period
Amortization period of co-promotion fee
Represents the amortization period of co-promotion fee.
Preferred stock warrant liability
Represents the security that gives the holder the right to purchase shares of convertible preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Convertible Preferred Stock Warrants [Member]
Convertible Preferred Stock Warrant
Warrants to purchase convertible preferred stock (as converted)
Probability of success of the second tranche (as a percent)
Represents the percentage of likelihood that the second tranche of convertible preferred stock will succeed, used as an input to measure fair value.
Fair Value Assumptions Probability of Success of Second Tranche of Convertible Preferred Stock
Debt Instrument Number of Installments
Number of installments
Represents the number of installments for payment of the debt.
Debt Instrument Period after which Debt is Repayable
Period after which debt is repayable
Represents the period after the date of borrowing in which the debt is repayable under the agreement.
Debt Instrument Penalty Percentage on Prepayment within One Year of Origination
Prepayment penalties for prepayment within one year of the loan origination (as a percent)
Represents the percentage of prepayment penalties for prepayment within one year of the loan origination.
Debt Instrument Penalty Percentage on Prepayment within Two Years of Origination
Prepayment penalties for prepayment within two years of the loan origination (as a percent)
Represents the percentage of prepayment penalties for prepayment within two years of the loan origination.
Debt Instrument Penalty Percentage on Prepayment after Two Years of Origination
Prepayment penalties for prepayment after two years of the loan origination (as a percent)
Represents the percentage of prepayment penalties for prepayment after two years of the loan origination.
Debt Instrument Remaining Discount Amortization Period
Amortization period of debt discount
Represents the remaining amortization period for discount on the debt.
Accrued Consulting Fees Current
Accrued consulting fees
Carrying value, as of the balance sheet date, of obligations incurred through that date and payable for consulting fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Series C Convertible Preferred Stock [Member]
Series C convertible preferred stock
Represents information pertaining to the series C convertible preferred stock.
Class of Warrant or Right Number of Securities for which Warrants Became Exercisable
Number of shares for which warrant became exercisable
Represents the number of securities for which warrants became exercisable.
Class of Warrant or Right Number of Securities for which Warrants will become Exercisable upon Drawn of Second Term Loan
Number of shares for which warrant will become exercisable upon drawing the second term loan
Represents the number of securities for which warrants will become exercisable upon drawing the second term loan.
Warrants and Rights Note Disclosure [Text Block]
Convertible Preferred Stock Warrants
Disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.
Current Fiscal Year End Date
Award Type [Axis]
Term Loan One [Member]
Term loan
Represents term loan one of the reporting entity.
Weighted Average Basic and Diluted Shares Outstanding Pro Forma
Shares used in computing pro forma net loss per common share, basic and diluted
Represents the weighted average number of shares (units) outstanding in the calculation of pro forma basic and diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
Share Based Compensation Non Bonus Related
Stock-based compensation
The aggregate amount of noncash, equity-based employee remuneration for non-bonus related compensation. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
Redeemable Convertible Preferred Stock Liabilities Current
Preferred stock liability
Fair value of outstanding redeemable convertible preferred stock liabilities.
Share Based Compensation Bonus Related
Equity-based compensation
The aggregate amount of noncash, equity-based employee remuneration for bonus related compensation. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
Preferred Stock Warrants Issued
Fair value of preferred stock warrant liability
Represents the fair value of warrant issued during the period to purchase preferred stock.
Increase (Decrease) in Accrued Liabilities and Deferred Rent
Accrued liabilities and deferred rent
The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent.
Thyroid Cytology Partners
Employee and Non Employee Stock Option Excluding Bonus Compensation [Member]
Stock-based Compensation
An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation.
Fair value of outstanding warrants associated with redeemable convertible preferred stock. Upon conversion of the underlying preferred stock, the warrants automatically become exercisable for shares of the entity's common stock based on a conversion ratio.
Redeemable Convertible Preferred Stock Warrants
Preferred stock warrant liability
Employee Stock Option Bonus Compensation [Member]
Equity-based Compensation
An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as bonus related compensation.
Document Period End Date
Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block]
Concentrations of Credit Risk and Other Risks and Uncertainties
Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.
Medicare [Member]
Medicare
Represents information pertaining to Medicare, a significant third-party payer.
Aetna [Member]
Aetna
Represents information pertaining to Aetna, a significant third-party payer.
United Healthcare [Member]
United Healthcare
Represents information pertaining to United Healthcare, a significant third-party payer.
Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited
Number of major financial institutions with which the company's cash and cash equivalents are deposited
Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity.
Allowance for Doubtful Accounts [Abstract]
Allowance for Doubtful Accounts
Revenue Recognition Number of Criteria
Number of specified revenue recognition criteria
Represents the number of specified criteria for revenue recognition.
Temporary Equity Disclosure [Text Block]
Convertible Preferred Stock
Disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer.
Temporary Equity Number of Shares that May be Sold in Additional Closings
Number of shares that may be sold in additional closings
Represents the number of shares that may be sold in additional closings under the agreement.
Entity [Domain]
Number of additional closings
Represents the number of additional closings.
Number of Additional Closings
Temporary Equity Stock Issued During Period Shares
Number of shares issued
Represents the number of shares classified as temporary equity issued during the period.
Expenses for cytopathology testing and evaluation services
Represents the amount of expense for testing and evaluation services.
Testing and Evaluation Services Expense
Arrangements and Non-arrangement Transactions [Domain]
Represents the amount of end of term payment of debt.
Debt Instrument End of Term Payment Amount
Amount of end of term payment
End of term payment as a percentage of total outstanding principal balance
Represents the end of term payment as a percentage of total outstanding principal balance of debt.
Debt Instrument End of Term Payment as Percentage of Total Outstanding Principal
Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward]
Shares Available for Grant
Share Based Compensation Arrangement by Share Based Payment Award Options Vested Outstanding Number
Vested at the end of the period (in shares)
As of the balance sheet date, the number of shares into which fully vested stock options outstanding can be converted under the option plan.
Share Based Compensation Arrangement by Share Based Payment Award Options Expected to Vest Outstanding Number
Expected to vest at the end of the period (in shares)
As of the balance sheet date, the number of shares into which expected to vest stock options outstanding can be converted under the option plan.
Share Based Compensation Arrangement by Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price
Vested at the end of the period (in dollars per share)
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested.
Share Based Compensation Arrangement by Share Based Payment Award Options Expected to Vest Outstanding Weighted Average Exercise Price
Expected to vest at the end of the period (in dollars per share)
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are expected to vest.
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested options outstanding.
Share Based Compensation Arrangement by Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
Vested at the end of the period (in dollars)
Share Based Compensation Arrangement by Share Based Payment Award Options Expected to Vest Outstanding Aggregate Intrinsic Value
Expected to vest at the end of the period (in dollars)
Amount by which the current fair value of the underlying stock exceeds the exercise price of expected to vest options outstanding.
The weighted average grant-date fair value of options exercised during the reporting period.
Share Based Compensation Arrangement by Share Based Payment Award Options Exercises in Period Weighted Average Grant Date Fair Value
Weighted average fair value of stock options exercised (in dollars per share)
Bonuses Paid Through Share Based Compensation Percentage
Percentage of executive bonus to be paid through grant of stock options
Represents the percentage of executive bonuses to be paid through share-based compensation for fiscal year.
Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value
Genzyme Co-promotion Agreement
Genzyme
Represents information pertaining to Genzyme Corporation, a co-promoter.
Genzyme Corporation [Member]
Document and Entity Information
Represents the period of prior notice for termination of the agreement.
Collaborative Arrangement Prior Notice Period for Termination of Agreement
Prior notice period for termination of agreement
Employee Stock Option Excluding Bonus Compensation [Member]
Stock-based Compensation, employee
An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation.
An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation.
Non Employee Stock Option Excluding Bonus Compensation [Member]
Stock-based Compensation, non-employee
An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as annual bonus related compensation.
Employee Stock Option Annual Bonus Compensation [Member]
Equity-based Compensation, executive bonus
Employee Stock Option Performance Bonus Compensation [Member]
An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as bonus compensation related to specified performance.
Equity-based Compensation, incentive stock options
Represents the percentage of cash receipts of co-promotion fees that have been received by the co-promoter under the agreement.
Collaborative Arrangement Percentage of Cash Receipts of Co-Promotion Fees
Percentage of cash receipts of co-promotion fees received by co-promoter
$0.08
Represents the exercise price of 0.08 dollars per share.
Exercise Price Dollars 0.08 [Member]
Exercise Price Dollars 0.80 [Member]
$0.80
Represents the exercise price of 0.80 dollars per share.
$2.36
Represents the exercise price of 2.36 dollars per share.
Exercise Price Dollars 2.36 [Member]
Exercise Price Dollars 2.40 [Member]
$2.40
Represents the exercise price of 2.40 dollars per share.
Exercise Price Range from Dollars 0.08 to Dollars 7.92 [Member]
$0.08-7.92
Represents the range of exercise prices from 0.08 dollars to 7.92 dollars per share.
Exercise Price Dollars 7.92 [Member]
$7.92
Represents the exercise price of 7.92 dollars per share.
Represent the percentage of co-promotion fee required to be repaid if the entity terminates the agreement without cause during period one.
Collaborative Arrangement, Percentage of Co Promotion Fee Repaid Termination of Agreement Period One
Percentage of co-promotion fee required to be repaid if agreement terminated prior to January 2014
Collaborative Arrangement, Percentage of Co Promotion Fee Repaid Termination of Agreement Period Two
Percentage of co-promotion fee required to be repaid if agreement terminated between January 2014 and January 2015
Represent the percentage of co-promotion fee required to be repaid if the entity terminates the agreement without cause during period two.
Collaborative Arrangement, Percentage of Co Promotion Fee Repaid Termination of Agreement Period Three
Percentage of co-promotion fee required to be repaid if agreement terminated between January 2015 and January 2016
Represent the percentage of co-promotion fee required to be repaid if the entity terminates the agreement without cause during period three.
Organization and Summary of Significant Accounting Policies [Table]
Disclosure for all significant accounting policies of the reporting entity.
Organization and Summary of Significant Accounting Policies [Line Items]
Overview
Collaborative Arrangement Co Promotion Expenses
Co-promotion expenses
Represents the amount of co-promotion expenses incurred under the agreement.
Collaborative Arrangement Outstanding Obligation
Outstanding obligation to Genzyme
Represents the amount of outstanding obligation under the agreement.
Class of Warrant or Right Number of Shares of Preferred Stock Warrants Converted
Preferred stock warrants converted (in shares)
Represents the number of shares of preferred stock warrants converted.
Class of Warrant or Right Shares of Common Stock Warrants Issued Upon Conversion of Shares of Preferred Stock Warrants
Warrants issued to purchase common stock upon conversion of preferred stock warrants (in shares)
Represents the number of shares of common stock warrants issued upon conversion of shares of preferred stock warrants.
Underwriting Discounts and Commissions
Underwriting discounts and commissions
Represents the amount of underwriting discounts and commissions payable by the entity.
Estimated Offering, Expenses
Represents the amount of estimated offering expenses payable by the entity.
Estimated offering expenses
Preferred Stock Number of Series
Number of series in which preferred stock may be issued.
Number of series in which preferred stock may be issued
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Legal Entity [Axis]
Document Type
Organization and Summary of Significant Accounting Policies
Accounts payable
Accounts Payable [Member]
Accrued Liabilities
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accounts Receivable, Net, Current
Accounts receivable, net of allowance of $364 and $222 as of September 30, 2013 and December 31, 2012
Accounts payable
Accounts Payable, Current
Outstanding obligations
Accounts receivable
Accounts Receivable [Member]
Accrued liabilities
Accrued Liabilities [Member]
Accrued Genzyme co-promotion fees
Accrued Marketing Costs, Current
Accrued liabilities
Accrued Liabilities, Current
Accrued liabilities
Accrued liabilities associated with employee and executive bonus plans
Accrued Bonuses, Current
Accrued legal and professional fees
Accrued Professional Fees, Current
Additional paid-in capital
Additional Paid in Capital, Common Stock
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Share-based compensation expense
Allocated Share-based Compensation Expense
Accounts receivable, allowance (in dollars)
Allowance for Doubtful Accounts Receivable, Current
Allowance for doubtful accounts
Write-offs for allowance for doubtful accounts
Allowance for Doubtful Accounts Receivable, Write-offs
Amortization of debt discount and issuance costs
Amortization of Financing Costs and Discounts
Amortization of debt discount and accretion
Antidilutive Securities [Axis]
Outstanding common stock equivalents excluded from the computation of diluted net loss per common share
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Outstanding common stock equivalents (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Total assets
Assets
Assets, Current [Abstract]
Current assets:
Assets [Abstract]
Assets
Assets, Current
Total current assets
Financial Assets
Assets, Fair Value Disclosure
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Capitalized costs
Capitalized Computer Software, Additions
Restricted Cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash and cash equivalents
Cash and Cash Equivalents
Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]
Chief Executive Officer
Chief Executive Officer [Member]
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Exercise price (in dollars per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants (in dollars per share)
Number of shares of preferred stock that can be purchased by each warrant
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Convertible preferred stock warrant
Class of Warrant or Right [Line Items]
Class of Stock [Domain]
Class of Warrant or Right [Table]
Variable Interest Entity, Classification [Domain]
Genzyme Co-promotion Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Co-promotion agreement
Collaborative Arrangement, Co-promotion [Member]
Genzyme Co-promotion Agreement
Collaborative Arrangement Disclosure [Text Block]
Commitments and contingencies
Commitments and Contingencies
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Common stock, $0.001 par value; 77,000,000 shares authorized; 992,578 and 667,684 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012, respectively
Common Stock, Value, Issued
Common stock, shares issued
Common Stock, Shares, Issued
Common stock, shares authorized
Common Stock, Shares Authorized
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Bonus Accruals
Compensation Related Costs, Policy [Policy Text Block]
Concentration Risk Type [Domain]
Concentrations of Credit Risk and Other Risks and Uncertainties
Concentration Risk [Line Items]
Concentration Risk Benchmark [Domain]
Concentration Risk Type [Axis]
Concentration Risk [Table]
Concentration Risk Benchmark [Axis]
Concentrations of credit risk (as a percent)
Concentration Risk, Percentage
Convertible preferred stock converted to common stock (in shares)
Conversion of Stock, Shares Converted
Convertible preferred stock (as converted)
Convertible Preferred Stock [Member]
Preferred stock liability
Common stock issued upon conversion of each preferred stock (in shares)
Convertible Preferred Stock, Shares Issued upon Conversion
Cost of revenue
Cost of Revenue
Cost of revenue
Cost of Sales [Member]
Gross receivables concentration risk
Credit Concentration Risk [Member]
Revenue concentration risk
Customer Concentration Risk [Member]
Debt
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table]
Debt Instrument, Face Amount
Amount drawn down
Amount drawn down of term loan
Debt
Debt
Debt Disclosure [Text Block]
Interest rate (as a percent)
Debt Instrument, Interest Rate, Stated Percentage
Borrowing capacity available for second term loan
Debt Instrument, Unused Borrowing Capacity, Amount
Deferred rent, net of current portion
Deferred Rent Credit, Noncurrent
Unamortized balance of the co-promotion fee
Deferred Revenue
Deferred Genzyme co-promotion fee
Deferred Revenue, Current
Deferred Genzyme co-promotion fee, net of current portion
Deferred Revenue, Noncurrent
Depreciation and amortization
Depreciation, Depletion and Amortization
Stock Incentive Plan
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Stock Incentive Plan
Outstanding obligations
Due to Related Parties, Current
Pro forma net loss:
Earnings Per Share, Pro Forma [Abstract]
Calculation of basic and diluted net loss per common share
Earnings Per Share, Basic and Diluted [Abstract]
Net loss per common share, basic and diluted (in dollars per share)
Earnings Per Share, Basic and Diluted
Net Loss per Common Share
Earnings Per Share [Text Block]
Net Loss per Common Share
Earnings Per Share, Policy [Policy Text Block]
Net Loss per Common Share
Accrued compensation expenses
Employee-related Liabilities, Current
Anticipated grants accrual
Stock-based compensation
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock options
Employee Stock Option [Member]
Period over which unrecognized compensation expense expected to be recognized
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Unrecognized compensation expense
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options
Bonus Accruals
Employee-related Liabilities, Current [Abstract]
Total
Estimate of Fair Value Measurement [Member]
Measurement Frequency [Axis]
Expected volatility (as a percent)
Fair Value Assumptions, Expected Volatility Rate
Change in value of preferred stock liability
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Hierarchy [Axis]
Liability Class [Axis]
Settlement of preferred stock liability
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Fair value measurements
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Recurring
Fair Value, Measurements, Recurring [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Table]
Fair Value, Measurement Frequency [Domain]
Risk-free interest rate (as a percent)
Fair Value Assumptions, Risk Free Interest Rate
Asset Class [Axis]
Change in value of preferred stock warrant liability
Fair Value Adjustment of Warrants
Change in fair value of preferred stock warrant liability recorded in other income (expense), net
Amount of change in the fair value reported as an expense in other income (expense), net
Fair Value by Liability Class [Domain]
Contractual term
Fair Value Assumptions, Expected Term
Term
Assumptions used to calculate fair value of liability using the option-pricing method
Assumptions used to calculate fair value of warrant upon issuance using Black-Scholes option-pricing valuation model
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Assumptions used to calculate fair value of preferred stock liability using the option-pricing method
Fair value measurements
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected dividend yield (as a percent)
Fair Value Assumptions, Expected Dividend Rate
Balance at the beginning of the period
Balance at the end of the period
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Fair Value Measurements
Fair Value Hierarchy [Domain]
Asset Class [Domain]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Summary of the changes in the fair value of the Company's Level III financial liabilities, which are measured on a recurring basis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Level III
Fair Value, Inputs, Level 3 [Member]
Changes in the fair value of the company's Level III financial liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value measurements
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Level I
Fair Value, Inputs, Level 1 [Member]
Level II
Fair Value, Inputs, Level 2 [Member]
Change in fair value of preferred stock liability recorded in other income (expense), net
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
General and administrative
General and Administrative Expense
General and administrative
General and Administrative Expense [Member]
Health Care Organization, Revenue Sources [Domain]
Health Care Organization, Revenue Sources [Axis]
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Income Statement Location [Axis]
Income Taxes
Income Taxes
Income Tax Disclosure [Text Block]
Income Statement Location [Domain]
Accounts receivables
Increase (Decrease) in Accounts Receivable
Accounts payable
Increase (Decrease) in Accounts Payable
Other assets
Increase (Decrease) in Other Noncurrent Assets
Co-promotion fee received from Genzyme
Deferred Genzyme co-promotion fee
Increase (Decrease) in Deferred Revenue
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Supplies inventory
Increase (Decrease) in Inventories
Prepaid expenses and current other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Change in restricted cash
Increase (Decrease) in Restricted Cash
Interest expense
Interest Expense
Interest on debt balloon payment
Interest Expense, Debt
Internal-use Software
Internal Use Software, Policy [Policy Text Block]
Inventory, Net
Supplies inventory
Supplies Inventory
Inventory Supplies, Policy [Policy Text Block]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Total current liabilities
Liabilities, Current
Total liabilities, convertible preferred stock, and stockholders' (deficit) equity
Liabilities and Equity
Current liabilities:
Liabilities, Current [Abstract]
Total liabilities
Liabilities
Liabilities, Convertible Preferred Stock, and Stockholders' (Deficit) Equity
Liabilities and Equity [Abstract]
Financial Liabilities
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Fair value of liability
Reimbursement for licensure fees
License Costs
Maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Line of Credit [Member]
Loan and security agreement
Thyroid Cytology Partners
Long-term Contracts or Programs Disclosure [Text Block]
Amount drawn down of term loan
Long-term Debt, Excluding Current Maturities
Long-term debt, net of discount
Maximum
Maximum [Member]
Minimum
Minimum [Member]
Money market funds
Money Market Funds [Member]
Financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net increase (decrease) in cash and cash equivalents
Net Cash Provided by (Used in) Continuing Operations
Net loss
Net Income (Loss) Available to Common Stockholders, Basic
Net loss used in computing pro forma net loss per common share, basic and diluted
Net loss and comprehensive loss
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Recent Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Number of operating segments
Number of Operating Segments
Operating expenses:
Operating Expenses [Abstract]
Total operating expenses
Operating Expenses
Loss from operations
Operating Income (Loss)
Organization and Summary of Significant Accounting Policies
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Other assets
Other Assets, Noncurrent
Fair value of currently exercisable portion of the warrant
Aggregate fair value of the warrant for the shares exercisable under the warrant
Other Liabilities, Fair Value Disclosure
Other Cost of Services
Reimbursed professional licensure fees
Other income (expense), net
Other Nonoperating Income (Expense)
Accrued other
Other Accrued Liabilities, Current
Accrued Liabilities
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share
Number of shares of preferred stock authorized
Preferred Stock, Shares Authorized
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Initial Public Offering and Reverse Stock Split
Proceeds from Issuance or Sale of Equity [Abstract]
Proceeds from the issuance of long-term debt, net of debt issuance costs
Proceeds from Issuance of Long-term Debt
Proceeds from Issuance Initial Public Offering
Net proceeds from issuance of common stock in IPO
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
Proceeds from Issuance of Redeemable Convertible Preferred Stock
Gross proceeds from issuance of shares
Proceeds from the exercise of common stock options
Proceeds from Stock Options Exercised
Estimated useful life
Property, Plant and Equipment, Useful Life
Property and equipment, net
Property, Plant and Equipment, Net
Net book value
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Axis]
Internal-use Software
Property, Plant and Equipment [Line Items]
Bad debt expense
Provision for Doubtful Accounts
Provision for bad debt expense
Range [Axis]
Range [Domain]
Allowance for Doubtful Accounts
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]
Genzyme co-promotion fee amortization
Amortization of co-promotion fee
Recognition of Deferred Revenue
Related Party [Axis]
Related Party [Domain]
Research and development
Research and Development Expense
Research and development
Research and Development Expense [Member]
Deposits
Restricted Cash and Cash Equivalents
Restricted Cash
Restricted Cash and Investments [Abstract]
Restricted Cash and Cash Equivalents, Current
Restricted cash
Certificate of deposit
Restricted cash
Restricted Cash and Cash Equivalents, Noncurrent
Letter of credit serving as security for lease
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Revenue Recognition
Revenue Recognition [Abstract]
Revenue Recognition
Revenue Recognition, Policy [Policy Text Block]
Weighted-average expected term
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term
Exercise price (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price
Weighted average fair value of stock options vested (in dollars per share)
Fair value (in dollars per share)
Fair value of fully vested stock options (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Contractual term
Options Outstanding, Weighted-Average Remaining Contractual Life
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term
Revenue, Net
Revenue
Revenue
Sales Revenue, Net [Member]
Forecast
Scenario, Forecast [Member]
Schedule of the fair value of the Company's financial assets and liabilities measured on a recurring basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of outstanding common stock equivalents excluded from the computation of diluted net loss per common share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Summary of activity under the Company's 2008 Stock Plan, including grants to non-employees and restricted stock issued
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Schedule of assumptions used to calculate estimated grant date fair value of employee stock options using the Black-Scholes option-pricing valuation model
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of accrued liabilities
Schedule of Accrued Liabilities [Table Text Block]
Schedule of the calculation of basic and diluted net loss per common share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Summary of share-based compensation expense
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Property, Plant and Equipment [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]
Summary of outstanding and exercisable stock options
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
Schedule of Variable Interest Entities [Table]
Schedule of the Company's significant third-party payers and their related revenue as a percentage of revenue
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Selling and marketing
Selling and Marketing Expense
Selling and marketing
Selling and Marketing Expense [Member]
Weighted Average Exercise Price per Share
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options granted (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Exercise price (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Options forfeited (in dollars per share)
Weighted-average volatility, high end of range (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Weighted-average volatility, low end of range (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Additional options authorized (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Share-based Compensation
Risk-free interest rate, high end of range (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Options granted (in shares)
Options granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Options granted in the future under the 2008 Stock Plan (in shares)
Stock incentive plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock value (in dollars per share)
Share Price
Fair value of preferred stock (in dollars per share)
Estimated fair value common stock (in dollars per share)
Grant date fair market value (in dollars per share)
Issuance price per share in IPO (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, low end of range (as a percent)
Options exercised (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Expected dividend yield (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Options forfeited (in shares)
Options forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Additions disclosures
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Balances at the beginning of the period (in shares)
Balances at the end of the period (in shares)
Intrinsic value of stock options exercised (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Weighted-average volatility (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Risk-free interest rate (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Weighted average fair value of stock options granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Balances at beginning of the period (in dollars per share)
Balances at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Balances at beginning of the period (in shares)
Balances at the end of the period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Outstanding and exercisable stock options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances at the end of the period (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Balances at beginning of the period (in dollars)
Exercise Price Range [Axis]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]
Options Outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Equity Award [Domain]
Exercise price, low end of range (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit
Options Outstanding, Number
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options
Options Vested and Exercisable, Number
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options
Exercise price, high end of range (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit
Capitalized software
Software Development [Member]
CONDENSED STATEMENTS OF CASH FLOWS
CONDENSED BALANCE SHEETS
Class of Stock [Axis]
Options exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Number of shares issued and sold in IPO
Stock Issued During Period, Shares, New Issues
Options to purchase common stock
Equity Option [Member]
Common stock issued on automatic conversion of outstanding convertible preferred stock (in shares)
Stock Issued During Period, Shares, Conversion of Convertible Securities
Stockholders' (deficit) equity:
Stockholders' Equity Attributable to Parent [Abstract]
Total stockholders' (deficit) equity
Stockholders' Equity Attributable to Parent
Reverse stock split ratio
Stockholders' Equity Note, Stock Split, Conversion Ratio
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
Subsequent Event [Table]
Subsequent Events
Subsequent Event [Line Items]
Subsequent Events
Subsequent Event [Member]
Subsequent events
Subsequent Event Type [Domain]
Subsequent Event Type [Axis]
Convertible preferred stock, shares outstanding
Temporary Equity, Shares Outstanding
Convertible preferred stock, par value (in dollars per share)
Temporary Equity, Par or Stated Value Per Share
Convertible preferred stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized
Temporary Equity, Shares Authorized
Number of authorized shares
Convertible Preferred Stock
Convertible preferred stock; $0.001 par value, 60,187,700 and 59,147,999 shares authorized at September 30, 2013 (unaudited) and December 31, 2012, respectively; 59,989,268 and 53,084,507 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012, respectively
Temporary Equity, Redemption Value
Convertible preferred stock, shares issued
Temporary Equity, Shares Issued
Temporary Equity, by Class of Stock [Table]
Title of Individual [Axis]
Relationship to Entity [Domain]
Type of Arrangement and Non-arrangement Transactions [Axis]
Unrecognized tax benefits, which if recognized, would affect the effective tax rate
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Unrecognized tax benefit
Unrecognized Tax Benefits
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Variable Interest Entities [Axis]
Thyroid Cytology Partners
Variable Interest Entity, Not Primary Beneficiary [Member]
Thyroid Cytology Partners
Variable Interest Entity [Line Items]
Convertible Preferred Stock Warrants
Warrant [Member]
Warrants to purchase convertible preferred stock
Convertible Preferred Stock Warrants
Pro forma adjustments to reflect assumed conversion of convertible preferred stock (in shares)
Weighted Average Number Basic Shares Outstanding Adjustment, Pro Forma
Weighted Average Number of Shares Outstanding, Basic and Diluted
Shares used to compute net loss per common share, basic and diluted (in shares)